Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Medicus Pharma Ltd ( (MDCX) ) has issued an announcement.
Medicus Pharma reported audited full-year 2025 results and detailed substantial clinical progress, highlighted by positive Phase 2 topline data for its SkinJect microneedle-delivered doxorubicin in nodular basal cell carcinoma, with up to 73% clearance in the highest dose cohort and early signals that most treated patients may avoid immediate surgery. The company is expanding SkinJect into Gorlin Syndrome with a planned Expanded Access program and potential orphan positioning, while pursuing a non-binding collaboration with Helix Nanotechnologies to combine its microneedle platform with next-generation mRNA for thermostable vaccines.
In urology and women’s health, Medicus advanced Teverelix, a long-acting GnRH antagonist targeting cardiovascular high-risk advanced prostate cancer and acute urinary retention, and is exploring its use in symptomatic endometriosis via genomics-enabled, biomarker-driven trial designs. The company also entered a non-binding collaboration with Reliant AI to build an agentic AI-driven clinical development platform aimed at optimizing trial design, patient stratification and dose selection, supporting more capital-efficient development and reinforcing its strategic positioning ahead of potential registrational plans and partnerships.
The most recent analyst rating on (MDCX) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Medicus Pharma Ltd stock, see the MDCX Stock Forecast page.
Spark’s Take on MDCX Stock
According to Spark, TipRanks’ AI Analyst, MDCX is a Neutral.
The score is primarily constrained by weak financial performance (no revenue, widening losses, and heavy cash burn with negative equity) and bearish technicals (price below all major moving averages with negative MACD). Valuation is difficult to assess due to negative earnings and no dividend support, while recent financing provides some liquidity benefit but reinforces dilution/financing dependence.
To see Spark’s full report on MDCX stock, click here.
More about Medicus Pharma Ltd
Medicus Pharma Ltd. is a biotech and life sciences company developing novel and potentially disruptive therapeutic assets across dermatology, urology, oncology, rare disease and women’s health. Its lead programs include the SkinJect microneedle immuno-oncology platform for non-melanoma skin diseases and the Teverelix GnRH antagonist franchise targeting prostate and women’s health indications.
Average Trading Volume: 3,784,862
Technical Sentiment Signal: Sell
Current Market Cap: $12.77M
Learn more about MDCX stock on TipRanks’ Stock Analysis page.